Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner
Launched by UNIVERSITY OF NOTTINGHAM · Mar 5, 2013
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Purpose for this study:
This research group has previously investigated the usefulness of a powerful new MRI scanner and have found that the 7 Tesla MRI is able to provide detailed structural images of the cortex of the brain which can uncover pathology such as cortical demyelinating lesions in MS patients. Multiple sclerosis (MS) affects the grey matter as well as the white matter of the brain and spinal cord. However as white matter lesions are more easily visible both pathologically and on MRI, therefore most MS research has focused on white matter demyelination. The investigators would...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patients with MS or other neurological disease which already had at least 1 MRI scan.
- • Healthy volunteers which had no indication of neurological disease in the past.
- • Do not have significant cognitive impairment and are able to give consent.
- • Will not have any contraindication for MR imaging
- • Are able to lie flat for up to 60 mins.
- • Age 25 and over.
- Exclusion criteria:
- • Pregnancy
- • Have any implants in the body.
- • Have aneurysm clips.
- • Have pacemaker or artificial heart valve.
- • Have foreign bodies in their body (e.g. shrapnel).
About University Of Nottingham
The University of Nottingham is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge research and expert faculty to address pressing medical challenges. Through its dedicated clinical trials unit, the University of Nottingham conducts rigorous studies aimed at improving patient outcomes and contributing to the global body of medical knowledge. The institution prioritizes ethical practices and participant safety, ensuring that all trials are designed to uphold the highest standards of scientific integrity and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Nikos Evangelou, PhD
Principal Investigator
University of Nottingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials